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Abstract. We investigated the feasibility of a novel method for hyperspectral mapping of macular pigment (MP)
in vivo. Six healthy subjects were recruited for noninvasive imaging using a snapshot hyperspectral system. The
three-dimensional full spatial-spectral data cube was analyzed using non-negative matrix factorization (NMF),
wherein the data was decomposed to give spectral signatures and spatial distribution, in search for the MP
absorbance spectrum. The NMF was initialized with the in vitro MP spectrum and rank 4 spectral signature
decomposition was used to recover the MP spectrum and optical density in vivo. The recovered MP spectra
showed two peaks in the blue spectrum, characteristic of MP, giving a detailed in vivo demonstration of these
absorbance peaks. The peak MP optical densities ranged from 0.08 to 0.22 (mean 0.15+ /− 0.05) and became
spatially negligible at diameters 1100 to 1760 μm (4 to 6 deg) in the normal subjects. This objective method was
able to exploit prior knowledge (the in vitro MP spectrum) in order to extract an accurate in vivo spectral analysis
and full MP spatial profile, while separating the MP spectra from other ocular absorbers. Snapshot hyperspectral
imaging in combination with advanced mathematical analysis provides a simple cost-effective approach for MP
mapping in vivo. C©2011 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.3640813]
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1 Introduction
The role of macular pigment (MP) in ocular health and disease
remains controversial. It has been suggested as a scavenger for
a reactive oxygen species and a blue light filter, and, hence,
to have a protective role against light-induced damage to the
photoreceptor/RPE complex.1, 2 Lutein (L) and zeaxanthin (Z),
the carotenoids that constitute MP,3 have antioxidant proper-
ties that appear to be protective against blue light.4 The optical
filtering properties of MP, to reduce chromatic aberration and
glare, have also been described.1 Its role in age-related mac-
ular degeneration (AMD) remains controversial. While some
have proposed a preventative role,5, 6 others have disputed this
role in their populations of AMD.7, 8 Furthermore, the ability
to modify the density of macular pigment through dietary sup-
plements remains an important, yet unanswered question. Most
studies have shown a significant relationship and this has been
comprehensively reviewed.9, 10
MP measures are subject to large amounts of variability in
normal subjects.11–13 An obstacle to clearly establishing the role
of MP in retinal disease is the lack of a validated, clinically ap-
plicable, and widely accessible tool to quantify the MP in vivo.
Noninvasive MP assessment methods include psychophysical
techniques and objective measures. Psychophysical methods
such as the matching tasks of heterochromic flicker photometry
(HFP) (Refs. 12, 14–16) or minimum motion photometry17, 18
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assume normal retinal function and uniform lens density within
the area of measurement and rely on the accuracy of patient
responses. Patients with advanced ocular disease tend to expe-
rience the greatest difficulty with such tests.15 Commercially
available psychophysical measures of MP generate a single
value, rather than a complete profile of measures for each eccen-
tricity. Objective methods include reflectance imaging,19–21 aut-
ofluorescence (AF) imaging,22–24 and Raman spectroscopy.25, 26
Reflectance and AF imaging give the spatial distribution of MP,
but in some cases require accurate fixation and require pre-
bleaching to avoid confounding absorption by photopigments,
which involves unpleasant light levels. Reflectance measures are
affected by stray light, unless confocal imaging is used. The AF
technique assumes that the relative spectral energy of lipofus-
cin fluorescence is constant across the central retina.3 Despite
the high chemical specificity of Raman spectroscopy, its sig-
nal can be attenuated by lenticular absorbance or scattering and
maximal pupil dilation is required for measurement.3, 27
Hence, there is a need for a rapid, objective, and sim-
ple method to noninvasively evaluate the MP. In our previous
research,28, 29 we evaluated a hyperspectral reflectometry cam-
era, which captures a 20 deg field with 76 bands of spectral infor-
mation, in conjunction with a partially constrained unsupervised
data mining approach (blind source separation) to demonstrate
the spectra that colocalized with drusen. Here, we applied this
technique to quantify the MP in a group of healthy eyes in vivo.
Our results are comparable to measurements made with other
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Fig. 1 Color fundus images of six healthy subjects (N1 to N6). N1, N2, and N6 show darkly pigmented individuals, while N3 is lightly pigmented
(blond fundus).
reflectance approaches. There has been recent interest in hy-
perspectral imaging using a modified fundus camera and the
various systems have been briefly reviewed.30 Prior multispec-
tral retinal image analysis has been restricted, either in spatial
extent to single line scans31 or to pointwise acquisition,32 or
spectrally to a limited number of spectral bands.33–35 While
excellent focal analysis of MP has been possible with two wave-
length reflectance36, 37 or AF,36 we wanted to investigate the full
20 deg field with 76 bands of spectral information and explore
the use of blind source separation to obtain detailed spectral
characterization of MP in vivo.
2 Methods
2.1 Subjects
We recruited six healthy volunteers (mean age 32.8, ± 12.1,
range 22 to 55 years, three males and three females; Fig. 1) from
the University of Southern California. Each patient underwent a
complete eye exam followed by pupil dilation and imaging with
the hyperspectral camera. Photoreceptor pigment prebleaching
was not systematically attempted.
This study was approved by the institutional review boards
of the University of Southern California and Columbia Univer-
sity and adhered to the tenets of the Declaration of Helsinki
for research involving human subjects. Each participant gave
informed consent after explanation of the nature and possible
consequences of the study.
2.2 Hyperspectral Camera
To avoid image coregistration and motion artifacts in spectral
space, this camera employed a novel technique, computed tomo-
graphic imaging spectrometer (CTIS), for hyperspectral retinal
imaging. The hyperspectral imaging device consists of an imag-
ing spectrometer attached to a commercial fundus camera. This
device captures a full spatial-spectral image cube (20 deg field,
186 × 186 pixel spatial resolution) in a single camera flash. CTIS
uses diffractive optics to multiplex spatial-spectral information
onto a focal plane array. With less than 20 msec integration time,
the retinal CTIS system acquired 76 contiguous spectral bands
between 420 and 720 nm at 4 nm resolution38, 39 (Fig. 2), thus
obviating the need for subject immobilization for precise image
registration.40
2.3 Image Reconstruction
The images were reconstructed, using the previously described
approach.39 Briefly, expectation maximization algorithms are
employed on the diffraction pattern to reconstruct the image
cube. The reconstructed cubes were then anonymously trans-
ferred to Columbia University for further data analysis.
2.4 Data Analysis
We employed a data mining approach to explore and search
for constituent pigment spectra of the retina. In particular,
we focused on extracting the spatio-spectral MP signatures
in healthy subjects. An unsupervised learning algorithm called
non-negative matrix factorization (NMF) (Refs. 41 and 42) was
employed with a partial constraint in the form of a physiologic
meaningful initialization scheme. NMF as usually implemented
decomposes the data as a linear sum of sources times abun-
dances; specifically, NMF decomposes a multivariate dataset X
into two matrices: a matrix of spectral signatures S and their
corresponding spatial distribution A. NMF assumes the linear
model
X = AS, subject to A > 0, S > 0,
where X is the hyperspectral data, A is the matrix of non-
negative spatial abundance images, and S are the constituent
Fig. 2 Zeiss FF450+ fundus camera shown with CTIS attached. The
normal 35-mm format image from the Zeiss is field-stopped by the CTIS
(insert, bottom right) and relayed using demagnification through the
computer-generated holographic (CGH) grating (insert, middle right).
Diffraction patterns are shown (insert, top right).
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Fig. 3 Montage of a normal hyperspectral cube. The hypercube for N6 with 75 spectral bands starting from 420 to 720 nm. The montage shows post-
processed spectral bands, where the data was log10-transformed and each spectral band was normalized by its standard deviation. Negative values
have been clipped and replaced with 2.2E-16. The post-processed hyperspectral cube has a range [0,1]. The fundus clinically was dark-pigmented.
positive spectra.43, 44 Unlike principal component analysis, NMF
imposes positivity constraints on the spectra and spatial abun-
dance images, consistent with physical reality. Such constraints
yield a parts-based representation of the hyperspectral cube that
allows an individual signature to be obtained, i.e., its spatio-
spectral characterization, which has a physically meaningful
interpretation.
We used NMF in a modified format on the hyperspectral
reflectance data cube to recover and investigate absorbance
signatures. To do this, the spectral reflectance R can be
written with the following simplified model (adapted from
Refs. 20 and 45):
R = RSC×10(−2D),
where RSC is the reflectance of the sclera and D is the total
optical density (OD) of all absorbers. To convert from reflectance
to absorbance the data is log-transformed, assuming D to be D
= ODMP + ODSubT, where MP denotes macular pigment and
SubT is the subtotal of all optical densities of all absorbers
except MP. For log10 of the data for each wavelength, we get
− log10(R) = − log10(RSC) + 2×ODMP + 2×ODSubT.
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Fig. 4 MP absorbance spectrum used for initializing the NMF algorithm. Circles denote the samples of the in vitro macular pigment spectrum. The
in vitro spectra of lutein (L) and zeaxanthin (Z) were obtained by Hammond et al. (Ref. 3). The dotted line denotes the fitted spectrum from 420 to
720 nm to be used for the NMF algorithm. Linear interpolation was used to fit the in vitro samples.
Thus, if after NMF applied to the above linear system we recover
the spectrum of MP, i.e., SMP, as one of the dominant spectral
sources, then at every pixel and for every wavelength λ we have
the decomposition
2×ODMP(λ) = AMP×SMP(λ),
where SMP is the recovered spectrum and AMP is its abundance.
It is customary to report the optical density at the absorbance
peak, λ = 458 nm, which is the target density mapped. In this
study, we reported the ODMP at λ = 456 nm due to spectral
resolution of X (i.e., 420 to 720 nm in 4 nm steps). In our case,
we alternatively performed NMF on the data model
log10(R) = log10(RSC) − 2×ODMP − 2×ODSubT
and later performed the sign change to reflect the optical density
of MP. The reason why a sign flip is required is due to the cost
function of the NMF objective. Thus, at every pixel we mapped
the optical density of MP as
ODMP(λ = 456) = −0.5×AMP×SMP(λ).
Note that although SMP may be constrained and normalized, say
with value = 1 at λ = 456 nm, it does not affect the recovery of
ODMP because the abundanceAMP is automatically scaled so that
the product gives the actual data. We note, that besides reporting
ODMP at 456 nm, the MP signature and abundance that NMF
returns has a much richer spatio-spectral representation than is
possible with other methods.
We performed the following normalization and initialization
scheme. First, we divided each spectral band of the cube by
its standard deviation to account for reflectance drifts along the
spectrum. After normalization, we log-transformed the cube as
just described and enforced positivity constraints on X to run
NMF on the post-processed data. An example of X can be seen
in Fig. 3.
The number of latent sources in the hyperspectral cube, i.e.,
the optimum rank of the matrix S of spectral signatures for
recovery of the MP spectrum, was experimentally determined
to be 4. For other ranks (e.g., 3 or 5) the decomposition of
the macular pigment spectra showed redundancies, i.e., similar
spectral profiles. In each case, we initialized one source as SMP,
the in vitro absorbance prior (Fig. 4), where all other sources
and abundance images were randomly initialized. However, SMP
was allowed to vary during the NMF algorithm to obtain the
best fit and most realistic spectrum. The obtained spatio-spectral
signatures of the MP were assessed and analyzed by two retinal
specialists (RTS, AF).
3 Results
3.1 Dataset Description
Figure 1 shows color fundus images of six normal eyes (N1 to
N6). The resolution of the color fundus RGB images was 1052
× 914. Figure 3 shows the post-processed hyperspectral cubes
of a healthy subject (N6).
3.2 Non-Negative Matrix Factorization Approach
Table 1 summarizes the employed configuration of NMF and
reports the number of iterations used, the reconstruction error in
terms of the root-mean-squared (RMS) error, and other conver-
gence specific results. The RMS error is defined as the square
root of the mean difference between the data X and the factor
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Table 1 Reconstruction error for healthy subjects (N1 to N6). ID de-
notes an identifier key for a hyperspectral cube or its corresponding
color fundus image, N is the number of iterations of the NMF algo-
rithm, RMS is the root-mean-square residual, and D is the maximal
change of either factor A or S.
Normals
ID N RMS D
N1 872 0.021399 0.00009994
N2 1000 0.024398 0.00037733
N3 1000 0.025532 0.00202895
N4 1000 0.018980 0.00013366
N5 1000 0.019192 0.00095528
N6 1000 0.021270 0.00068574
model AS. We used a rank r = 4 decomposition to search for the
known MP absorbance spectrum. Thus, if X is the hyperspectral
data set, NMF found a decomposition AS as an approximation
to X, where S is the matrix of rank 4 of spectral signatures and A
is the matrix of abundances. The factors A and S are chosen to
minimize the RMS betweenX andAS, as previously proposed.44
For all datasets in these experiments, 1000 iterations of the algo-
rithm resulted in a reconstruction error range of approximately
1 to 4% at each pixel.
3.3 Recovered Macular Pigment Spectra
and Optical Densities
Figure 5 shows the recovered MP spectra. In all six eyes, the
recovered spectra show the two nearby peaks in the blue charac-
teristic of both L and Z, the two carotenoids that constitute MP.3
We also found that fundus pigmentation did not have an impact
on the performance of this approach, with ODMP recovered in
blond (N3) as well as highly pigmented fundi (N1, N2, and
N6). The corresponding ODMP maps are shown in Fig. 6. ODMP
values ranged from 0.08 to 0.22 (mean 0.15 ± 0.05, Table 2).
Figure 7 shows a larger view of the ODMP map for subject N1
and corresponding MP density profile plot along the horizontal
meridian.
4 Discussion
The hyperspectral tool we have utilized herein is an integration
of highly novel imaging technology and the blind source sepa-
ration method of NMF. The high spectral resolution (4 nm) of
the CTIS multiplexing device coupled with the ability of NMF
to precisely detect a spectral signal and its abundance, have to-
gether achieved a detailed demonstration of the two absorbance
peaks of MP in normal eyes in vivo. To our knowledge, this
is the first demonstration of the bifid absorbance spectrum of
MP in vivo. Other researchers have attempted to fit their recov-
ered spectral signatures to known MP spectra,34 which is rather
different to our approach. The flexibility allowed by having mul-
tiple spectral points in the region of interest (21 measurements
Table 2 Macular pigment optical density (ODMP) for healthy subjects
(normals). ID denotes an identifier key for a hyperspectral cube or its
corresponding color fundus image, Max is the peak optical density
value within a two degree annuli centered at the fovea, Mean is the
average optical density within the same region as Max, and SD is its
standard deviation.
Normals
ID Max Mean SD
N1 0.14504 0.14243 0.00531
N2 0.22397 0.22117 0.00987
N3 0.10200 0.07576 0.01001
N4 0.16015 0.13787 0.01581
N5 0.18881 0.16846 0.01847
N6 0.17816 0.17613 0.00531
at each pixel in the region from 420 to 500 nm), and the use of
MP signature only to initialize NMF search, give this approach
the distinct advantage of reaching MP spectral signature based
on individual eye’s spatial/spectral data encoded in the hyper-
spectral cube. The accuracy of this method is demonstrated by
the highly resolved recovered spectral signal in normal subjects.
Moreover, the method is versatile in its ability to recover the
spectra of known or unknown reflectors and absorbers. While
in this project we used the known in vitro spectrum of MP to
guide the recovery of its abundance, we have previously uti-
lized the same blind source separation in a completely unsu-
pervised fashion to extract spectral signatures that consistently
co-localized with drusen.28, 29 Suggesting this approach can be
used to achieve important tasks in the study of the normal and
diseased fundus.
Advantages of this approach include its relative freedom from
dependence on visual acuity or fixation, which may be highly
valuable when evaluating patients with unstable and/or eccentric
fixation. This is one of the main limitations of psychophysical
approaches to MP assessments, such as HFP and customized
HFP. Another limitation of the psychophysical approach relates
to its basic assumption that ODMP is zero outside the central
5 deg, which leads to its systematic underestimation of ODMP
when compared with other approaches.36, 46–48 It was previously
shown that MP can still be present at low levels at 1 mm ec-
centricity (≈4 deg) in primate eyes49 and out to 8 deg in human
donor eyes.50 A residual signal in our data at more eccentric lo-
cations might be attributed to this low level. A further advantage
of the snapshot hyperspectral method is the capability to map a
complete spatial profile of MP. Other hyperspectral methods, al-
though they may use careful fits to models of fundus reflectance,
only acquire MP density at a single point, for example, a measure
of the averaged density in the central 1.9 deg.51 The snapshot
method acquires a full three-dimensional spectral-spatial cube,
which is simultaneously analyzed to measure MP density at
every point of a 4 mm square field at a resolution of 22 μm.
The limitations of this approach include the inherent re-
strictions of measuring MP with reflectance. Delori et al. have
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Fig. 5 Recovered spectra for normal subjects. The four spectra recovered by NMF for each of the six healthy subjects (N1-N6). The fourth spectrum
denotes the MP spectrum (solid line). The two peaks between 450 and 500 nm are the classic bifid spectrum previously reported (Ref. 3) in vitro.
The secondary peaks at 425 nm (N1, N2, N4, N5, and N6) have also been reported in vitro.
provided a detailed analysis showing that while MP measure-
ments are highly correlated among three different approaches,
reflectance values are much lower than other approaches, and
offered several explanations, including the presence of ante-
rior reflectors in the retina and lens scatter.36 The low ODMP
values obtained in our subjects are consistent with these pre-
vious findings obtained by reflectometry.36 Methods to correct
these errors include baseline spectral measures of lens scatter36
and model-based estimates of (anterior reflectance) foveal re-
flectance using four spectral lines.45 These corrections could be
implemented in future work. Another limitation may be related
to the possible chromatic aberrations and defocus inherent in
the spectral range at issue (420 to 500), although our dataset
showed essentially uniform image quality in this range (Fig. 3).
The optical density of the individual eye in principle should not
confound the NMF hyperspectral method for ODMP, because it
is contained in ODSubT, the separate term for other absorbers.
Absorption by incompletely bleached cone photoreceptor pig-
ment could also influence the hyperspectral data, but again, in
principle, these effects should be separated from the MP by the
NMF method, which specifically isolates the contribution from
the MP spectrum. In fact, there could be imperfect unmixing
of these signals. In the case of cones, the peak absorbances
of the short and medium wavelength cones are centered about
50 nm on either side of the peaks of the MP profile,52 hence,
they would have only a relatively small effect, similar to that
of photoreceptor absorbance on HFP depending on differential
absorption of blue and green light. Finally, the internal limiting
membrane reflectance signal is apparent in the clinical photos of
the younger normal subjects N2 and N6, and to a lesser extent
Fig. 6 Hyperspectral macular pigment optical density (ODMP) maps. Results of NMF applied to the corresponding hyperspectral data cubes, resulting
in abundance maps (not shown) that have been converted to ODMP maps at 456 nm (grayscale coded). In the six healthy subjects (N1 to N6), the
peak ODMP ranged from 0.08 to 0.22 (Table 2) and became negligible at 4 to 6 deg eccentricity, consistent with the known distribution of MP
(Ref. 53).
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Fig. 7 Detailed view of a hyperspectral macular pigment optical density (ODMP) map for subject N1 and macular pigment density profile plot.
A larger view of the ODMP map at 456 nm for subject N1 is shown (left) and a density profile plot along the horizontal meridian is given (right),
corresponding to the horizontal white dotted line.
in other images, overall, the effect of scattering due the internal
limiting membrane is small.51
It is important to note that approaches using differential
reflectance or AF images to calculate MP density maps rely
on major assumptions. For reflectance, the entire difference
in reflectance between a single blue and green wavelength is
attributed to MP. The NMF method makes no such assumptions
and instead uses the full spectral information in the 27 bands be-
tween 420 and 530 nm to fit the reflectance data to a detailed prior
model of the MP spectrum. Similarly, the AF method makes
several assumptions. First, the difference between AF intensity
centrally and peripherally is entirely due to the absorbance by
MP of blue light. Second, the relative spectral energy of lipofus-
cin fluorescence is constant across the central retina and, last,
that MP density is zero at a peripheral point, another potential
source of error for all comparison methods. Again, the strength
of the NMF method is that it directly searches for the absorber of
interest based on its own signature and specifically separates the
distribution of this signature from the other components of the
data. No assumptions are made or required about the distribution
of other absorbers and reflectors.
There are potential advantages and disadvantages to the gen-
eral NMF method and specifically to the use of an initialized
choice of spectral basis vector. The power of NMF lies in its
ability to extract meaningful spectra from data without prior
knowledge. For example, this would apply to the reflectance
spectra of drusen, which are unknown. In such cases, the initial
basis vectors are specified in number only (the rank of the de-
composition) and otherwise, the initial spectra can be virtually
random. This approach is the broadest but with no guarantee
that meaningful spectra will be recovered. However, NMF is
also used in the context where a specific approximate spectral
signal is known to be present in the data. Thus, the power of
the NMF approach with prior knowledge is that, by specifying
one initial basis vector for the in vivo spectrum of MP, the al-
gorithm is already “close” to a solution. During the solution,
the algorithm modifies the initial basis vector and calculates
its spatial distribution as necessary to find the best objective fit
to real closely-spaced spatio-spectral data. Recovery of both a
physiologically reasonable MP spectrum and density profile in
turn, provides substantial evidence that the NMF method has
effectively identified the MP and separated it from other ocu-
lar absorbers, even though no other absorbers were explicitly
modeled.
Realistically, no spectral separation will be perfect. Some of
the abundance images for MP in normal eyes show signal in
the retinal vessels, suggesting that hemoglobin absorbance has
not been completely separated from the MP spectrum. Indeed,
because we did not explicitly include hemoglobin absorbance
spectra in our other basis vectors, a slight hemoglobin admix-
ture would be expected. Moreover, the MP distributions in other
published methods highlight the vessels,20, 23, 27 suggesting that
a complete separation of hemoglobin and MP has not yet been
achieved. A simple future solution would be an initial segmenta-
tion of the vessels, either manually or by automated techniques.
A more sophisticated solution, directly amenable to NMF, would
be to search for hemoglobin basis vectors.
A future goal will be to separately measure L and Z. Their
spectra are similar, with Z shifted to the red by 10 nm. We be-
lieve that this should be possible to achieve with our method, as
suggested by the fact that separate L and Z optical densities have
been measured using fundus reflectometry with 5.8 nm resolu-
tion in vivo32 (although the actual spectra were not recovered in
this experiment). Our method has shown the ability to resolve
peaks 10 nm apart, hence, it should also be able to recover the
L and Z spectra.
In summary, we have shown that the combination of a novel
hyperspectral imaging tool with advanced mathematical analysis
can, to the best of our knowledge, for the first time, recover de-
tailed spectral absorption curves for MP in vivo that correspond
to physically realistic retinal distributions. The calculated op-
tical densities are consistent with other reflectometry methods.
With regard to MP specifically, the ease, speed, and precision of
MP density acquisition suggests that further effort with known
methods is warranted to correct for error sources such as lens
scatter and pre-retinal reflectors. More generally, success with
MP suggests that this hyperspectral method will prove effec-
tive in recovering known and unknown spectra and densities of
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important ocular reflectors and absorbers. Among these, which
should be investigated, are drusen in age-related macular degen-
eration, whose complex biochemical composition is critical to
understanding the disease process.
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